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of eosinophilic asthma with the potential benefit of inhibiting
eosinophilic airway inflammation for at least 30 days after one
injection. A recent case report supports the use of benralizumab in
this way (10). Larger studies are needed to determine whether this
strategy is clinically effective and cost effective. n
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In-Parallel Ventilator Sharing during an Acute
Shortage: Too Much Risk for a Wider Uptake
To the Editor:
We read with interest the article by Beitler and colleagues on
ventilator sharing among patients with coronavirus disease
(COVID-19)–associated acute respiratory distress syndrome (1).
The COVID-19 pandemic has forced clinicians to develop
strategies to avoid denying care because of ventilator capacity
shortages induced by patient demand surges. Nevertheless, the
safety of these strategies has been difficult to guarantee, as
summarized in a recent multisociety consensus statement (2).
Beitler and colleagues implemented a careful protocol
for a shared, in-parallel (i.e., simultaneous, breathing-together)
ventilation circuit (1). Their methodology demonstrated the
feasibility of ventilator sharing but at the cost of several major
limitations we believe could prevent generalization or wider uptake,
including the following:
1. Patient compatibility criteria are crucial and require time and
expertise. Unfortunately, COVID-19 “overrun,” as we will call
it, is a situation in which time is “negative.” For many clinical
staff, there is little time or ability to spend matching patients
and monitoring it when patient course diverges. Many hospitals
worldwide do not have the nursing levels of the United States.
2. The patient-specific monitoring required is necessary but
adds circuit complexity, cost, and technology that may not
be available in many centers worldwide. It will also require
significantly more technical expertise than is available outside
major center hospitals.
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3. Rescue ventilators (as a safety measure if shared ventilation
fails) may not be available or may understandably also be in use
in such a situation.
4. Pressure control when patients breathe together does not
ensure that lung damage from divergent patient courses does
not occur. Driving pressure and barotrauma are an issue if
compliance rises significantly for one patient and similarly for
underventilation and a need for greater pressure in one patient.
This approach thus puts great weight on not only patient
matching but also matching and tracking patient course to
avoid damage. It may work in a limited trial and study but
not necessarily in a COVID-19 “overrun” situation, in which
staffing capability is stretched to the limit.
5. The authors state, “Patient selection and management
require considerable expertise to ensure safety. Therefore, we
recommend a regional referral model wherein ventilator sharing
is restricted to expert centers, and patients and ventilators move
throughout the region accordingly.” However, it requires
significant time, cost, and effort to move infectious patients.
It also implies greater risk for a select set of patients in the
receiving center(s), which may not be ethical or provide equity
of access to care for patients.
Importantly, we admire this result but feel in-parallel
ventilation carries too much risk and difficulty to implement safely.
We would thus draw the authors’ attention to the concept of
in-series breathing (patients breathe one after the other) in a simply
implemented active circuit (3) as a safer alternative. It allows
individualized positive end-expiratory pressure and driving
pressure to account for differences between patients and
reduces risk of harm because patients breathe separately (not
together).
Thus, Beitler and colleagues (1) developed excellent results in a
limited test situation but added significant complexity and cost per
patient, which may not be feasible in general or in COVID-19
overrun. The use of in-parallel breathing requires significant
matching of patient condition and monitoring of time course to
assess risks of barotrauma or volutrauma (even with pressure control)
as well as a risk of underventilation. All these risks are well-known
to be difficult to monitor and assess in the best of times. A COVID-
19 overrun situation demanding ventilator doubling is not the best
of times. We suggest in-series breathing as a safer solution. n
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Ventilator Sharing Using Volume-controlled
Ventilation during the COVID-19 Pandemic
To the Editor:
In a recent article, Beitler and colleagues described their
methodology and lessons learned from ventilator sharing during the
acute shortage caused by the coronavirus disease (COVID-19)
pandemic (1). We applaud their efforts during unprecedented
circumstances, as we similarly assessed the safety and feasibility of
ventilator sharing at a time of near depletion. In their assessment,
each patient was matched with identical ventilator settings before
sharing pressure-control ventilation. In our assessment, we used
the Vent Multiplexor device to modulate flow in a volume-control
mode and permit individual adjustments of VT to two patients.
At baseline, patient A had a VT of 350 ml (5.5 ml/kg predicted
body weight), driving pressure of 14 cm H2O with positive end-
expiratory pressure (PEEP) of 14 cm H2O, and pH 7.36 with
PaCO2 56 mm Hg; patient B had a VT of 450 ml (6.8 ml/kg
predicted body weight), driving pressure of 12 cm H2O with
PEEP of 10 cm H2O, and pH 7.42 with PaCO2 54 mm Hg. Each
had different static lung compliances (A = 25 ml/cm H2O; B = 37.5
ml/cm H2O). Both had a respiratory rate of 20 breaths/min and
required vasopressor support and neuromuscular blockade for the
assessment; neither had underlying lung disease. Before the
assessment, consent was obtained from both patients’ families.
The Vent Multiplexor was assembled within the circuit described
in Figure 1. In the assessment, the device was adjusted to deliver
different flow ratios to patients, with vitals, end-tidal carbon
dioxide, plateau pressures, and arterial blood gases monitored
over a 2-hour period.
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